Vanstar announces AGM results and the election of directors
Momentum Public Relations
Press Release: June 17, 2019
Vanstar Mining Resources Inc. announces that the seven candidates designated in the management proxy circular dated May 10, 2019 were elected to the Corporation’s Board of Directors during the shareholders’ annual meeting held in Longueuil on June 13, 2019.
The shareholders were represented in person or by proxy by 20,241,497 class A shares, or 42.65% of the 47,463,328 outstanding class A shares.
Voting results are presented below:
- Percentage of votes in favour of the nomination of the directors proposed varies from 82.78% to 100%. Thus, MM. Guy Morissette, Pascal Germain, Eric Beauchêsne, Eric Gervais, Gary Claytens, Jonathan Hamel and Martin Richard were re-elected directors of the company.
- The appointment of Brunet Roy Dubé, CPA, as Independent auditor for the Company was approved at 100%.
- The amendment of the stock option plan was approved at 88.77%.
Certain information contained in the press release are subject to receipt of all regulatory
approvals. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
For more information on Vanstar, visit our website at www.vanstarmining.com.
Source : Guy Morissette
President and CEO
819-763-5096
gmvanstar@gmail.com
- Published in Mining, News Home, Vanstar Mining
Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
Momentum Public Relations
Press Release: June 17, 2019
Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its non-controlled cannabinoid drug product PPP003 slated for the treatment of painful dry eye. The purpose of the meeting was to obtain confirmation of the Phase II clinical study design and the quality and toxicology requirements for initiating this trial in patients in the USA.
The FDA confirmed the proposed quality information requirements for initiating the Phase II trial in patients. This included a container closure system, stability plans, drug substance and drug product specifications. The FDA also provided feedback on the GLP toxicology requirements to initiate the Phase II trial.
The FDA reviewed the proposed Phase II clinical study and agreed that it was acceptable to evaluate the safety and efficacy of PPP003 Ophthalmic Solution for the treatment of the signs and symptoms of painful dry eye. The FDA also provided guidance on acceptable primary and secondary endpoints.
“This program is a corporate priority for Tetra and Panag since there is a significant unmet medical need for ophthalmic drugs,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “The choice of the non-controlled cannabinoid was important as the Company is aiming for global market penetration. We are extremely pleased that the U.S. FDA validated our ophthalmic research program. This program confirms that our research and development team is on the right track. With this confirmation and guidance, Tetra can now complete the execution of the clinical program for PPP003 intended to target the same important dry eye market as Xiidra™ which was recently acquired by Novartis from Takeda for $3.4Bn with $1.6Bn in potential milestone payments.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabinoids and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in News Home, Tetra Bio Pharma
Sirona Biochem Announces TFC-1067 Skin Lightening Patent Granted in USA
Momentum Public Relations
Press Release: June 17, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is pleased to announce that the patent for TFC-1067 entitled “Gem Difluorocompounds as Depigmenting or Lightening Agents” was granted in the USA, as expected, and will be published in the official database in the coming month. To date, the TFC1067 skin lightening patent has been granted in Germany, France, United Kingdom and now the US. Further TFC-1067 patent applications are in the patent pending status in multiple other countries while they go through the normal approval process.
TFC-1067, Sirona’s proprietary skin lightening compound, is superior to current actives on the market, safe and free of hydroquinone. The compound has undergone extensive testing, both preclinical and clinical, including a double blinded study for dyschromia in the US. Clinical results were received in late February 2019 and showed the compound to be superior to hydroquinone in the treatment of dyschromia with no adverse side effects. Sirona is currently in advanced negotiations in North America and Asia in regards to licensing rights for TFC-1067.
“This patent grant in one of the largest skin care markets is another important milestone for TFC-1067. The patent application was without concern to our potential partners as determined by their IP lawyers however it is an important and exciting milestone to reach,” said Dr. Howard Verrico, CEO of Sirona Biochem. “This will allow our potential US partners’ absolute IP certainty to move forward with their product marketing plans.”
The global skin lightening market is expected to reach $23 Billion USD by 2022[1].
About Sirona Biochem Corp
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Jonathan Williams
Managing Director
Momentum PR
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com
[1] https://www.factmr.com/report/309/skin-lightening-products-market
- Published in Life Sciences, News Home, Sirona Biochem
Sirona Biochem Appoints Chinese Lawyer Jason Tian to its Board of Directors
Momentum Public Relations
Press Release: June 12, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that Mr. Jason Tian will be joining its Board of Directors. Jason Tian is a Senior Partner at Landing Law offices based in Shanghai, China. Jason has been working with Sirona since 2018 representing the Company at strategic partnering meetings in China and France.
Jason Tian has been providing legal services to international clients since 2007 and has worked in top firms in China such as Beijing Zhonglun, Beijing Zhongyin, Beijing Dacheng and is now a Senior Partner of Shanghai Landing Law Offices. He also worked as senior legal translator in UK-based firm, Clifford Chance LLP, before starting his legal career.
Shanghai Landing Law Offices is a full-service law firm with headquarters in Shanghai, China. Lawyers at Landing provide full-service to clients in industries such as healthcare and pharmaceuticals as well as consumer retail in China. Landing has several domestic branches and overseas branches in the United States, India, Singapore, Indonesia, Bangladesh, Philippines and Cambodia.
“Sirona’s management team has developed an excellent working relationship with Jason. His legal knowledge and extensive network in the Chinese business community are proving to be tremendous assets to Sirona”, reports Sirona Biochem’s CEO Dr Howard Verrico.
The company also announces Casper Bych has resigned from Sirona’s Board of Directors.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law. The appointment of Jason Tian to the BOD is subject to exchange approval.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/12/c2009.html
Contact:
regarding this press release, please contact: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com
- Published in Business, Life Sciences, News Home, Sirona Biochem, Technology
Crystal Lake Mining’s Discovery Team Outlines Chachi Corridor Copper-Gold Target Area at Newmont Lake Project
Momentum Public Relations
Press Release: June 12, 2019
Crystal Lake Mining Corporation (TSXV: CLM) (OTC PINK: SIOCF) (FSE: SOG-FF) (“Crystal Lake” or the “Company“) is pleased to announce that a large copper-gold porphyry target area, with high-grade gold potential, has been outlined on the eastern side of the Company’s Newmont Lake Project in Northwest B.C.’s Eskay Camp.
The northeast trending Chachi Corridor along the McLymont fault system has a current strike length of greater than 8 km by 3 km wide as defined by an extensive review of historic data including rocks, soils and geophysics. The entire corridor, which features astonishing glacial retreat, is notably underexplored and will be one of several primary areas of focus for the 2019 summer exploration program, now underway.
Location
The Chachi Corridor begins approximately 6 km northeast of the historic Northwest Gold zone (“NW Zone”) and 20 km northeast of Crystal Lake’s recent drilling discovery at Burgundy Ridge (March 7, 2019, news release), underscoring both the scale and potential of the entire 430 sq. km Newmont Lake Project located in the heart of the Golden Triangle.
A broad and flat glacial valley ranging in elevation from 500 to 700 meters begins at the northeast tip of the Chachi Corridor and continues in a straight direction northeastward for approximately 20 km to the Galore Creek access road west of the Bob Quinn Airstrip. Additionally, infrastructure and access to the southern portion of the Newmont Lake Project have recently been upgraded with the completion and power production of AltaGas’ Northwest Hydroelectric facilities, including the 66-MW McLymont Creek power plant which sits at the southern tip of Crystal Lake’s land package 15 km northwest of Nickel Mountain.
Location of Crystal Lake Mining’s Newmont Lake Project in the prolific Eskay Mining Camp of Northwest BC, Canada
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6406/45530_7a9c6af784f39848_001full.jpg
Glacial Retreat Opens Corridor
Based on cross referencing old and new satellite imagery and orthographic photos, glacial retreat of approximately 2 to 4 kilometers has occurred within the Chachi Corridor since parts of it were last explored with “boots on the ground” in 2008. Widespread surface alteration, intrusive bodies and other geological features consistent with large-scale porphyry copper-gold and associated shear vein gold and/or carbonate replacement gold systems are apparent in the geochemical data compilation. This plus the newly exposed prospective ground makes the entire Chachi Corridor a high-priority target.
Satellite image showing the extent of glacial retreat along Chachi Corridor from 2002 to 2018
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6406/45530_7a9c6af784f39848_002full.jpg
Chachi Corridor Additional Highlights:
- Three separate intense geochemical anomalies (copper, gold and silver), vectoring into vast unexplored and highly altered terrain, covering an area greater than 8 km by 3 km;
- An approximate 3 km gossanous zone is adjacent to a cluster of dioritic and syenitic intrusions (typical intrusion types to host large porphyry systems and mineral occurrences in this region), all spatially associated with the McLymont Fault system of extensional tectonics in the region;
- A radiometric age-dating study at the University of British Columbia (“UBC”) concluded late Triassic ages of 203.1 ± 2.0 Ma to 214.1 ± 2.0 Ma on two sampled intrusions to date in the Chachi Corridor, which puts a copper-gold porphyry system in the Corridor remarkably similar in age to the Newmont/Teck Galore Creek/Copper Canyon deposits approximately 40 km to the northwest (Assessment Report #30749, B.C. Geological Survey);
- Limited historic rock sampling (late 1980’s) over a strike length of 1 km from an interpreted epithermal area on the eastern side of the Chachi Corridor returned values ranging from anomalous to 14.2 g/t Au, with 8 of the 28 samples grading >8 g/t Au (Assessment Report #18450).
Richard Savage, President and CEO of Crystal Lake, commented: “The right people, the right area, the right time – we’ve assembled an amazing team that’s planning an expansive initial exploration program that will be systematic and discovery-driven, applying state-of-the-art exploration technologies.”
Chachi Phase 1 Exploration Program
A team of approximately 20 people at any given time will be exploring and validating the Chachi Corridor. A Phase 1 program consisting of extensive prospecting, lithological and alteration mapping, airborne and ground geophysics, and geochemical and alteration vectoring using the latest in-field mobile hyperspectral and X-ray Fluorescence (“XRF”) technology should quickly define priority targets for drill testing this summer.
Corporate Update
Crystal Lake Mining is currently in the process of rebranding and building its new investor website, corporate presentation, geological and investor maps and more. To find out more about the company and to be notified when these items are available, email info@crystallakemining.com or sign-up on our current website to receive all email alerts.
Qualified Person
The technical information in this news release has been reviewed and approved by Mr. Abdul Razique, PhD., P.Geo., a Qualified Person responsible for the scientific and technical information in this news release under National Instrument 43-101 standards.
About Crystal Lake Mining
Crystal Lake Mining is a Canadian-based junior exploration company focused on building shareholder value through high-grade discovery opportunities in British Columbia and Ontario. The Company has an option to earn a 100% interest in the Newmont Lake Project, one of the largest land packages among juniors in the broader Eskay region in the heart of Northwest B.C.’s Golden Triangle.
This news release may contain certain “forward looking statements”. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Any forward-looking statement speaks only as of the date of this news release and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
On Behalf of the Board of Directors,
CRYSTAL LAKE MINING CORP.
“Richard Savage”
President & CEO
Email: info@crystallakemining.com
Website: www.crystallakeminingcorp.com
For further information please contact:
Momentum Public Relations
Tel: +1 (514) 815-7473
Email: mark@momentumpr.com
- Published in Crystal Lake Mining, Mining, News Home
CROP Announces Second Senior Secured Convertible Debenture Offering
Momentum Public Relations
Press Release: June 11, 2019
CROP Infrastructure Corp. (CSE: CROP) (“CROP” or the “Company”), announces that it intends to conduct a non-brokered private placement offering (the “Offering”) of senior secured convertible debentures (the “Debentures”) at an original issue discount of 20% with aggregate face value of up to $1,250,000 (the “Principal Amount”), for gross aggregate proceeds of up to $1,000,000.
The terms of the Debentures include:
- a maturity date of one year from the date of closing of the Offering (the “Closing”) and will bear interest at a rate of 10% per annum, payable quarterly in cash (the “Interest”);
- subject to adjustment, the holders of the Debentures, at any time, may convert all or any part of the Principal Amount outstanding under the Debentures into common shares of the Company (each, a “Conversion Share”) at a conversion price of $0.30 per Conversion Share (the “Conversion Price”) and with which any accrued and unpaid Interest may be converted into Conversion Shares at a conversion price of $0.30 per Conversion Share; and
- the Company may elect to repay, in cash, the outstanding Principal Amount of the Debentures, including any accrued and unpaid Interest, upon 30 days written notice any time following the initial 4 months from the date of Closing.
Each subscriber to the Offering shall receive one share purchase warrant (each, a “Warrant”) for each $0.30 of Principal Amount with each Warrant entitling the holder thereof to acquire one common share of the Company (each, a “Warrant Share”) at an exercise price of $0.50 per Warrant Share (the “Exercise Price”) for a period of 3 years from Closing.
If the Company undertakes an equity financing at a price per common share (each, a “Share”) (or having a conversion or exchange price) less than 95% of the closing market price per Share while the Debentures are outstanding, the Conversion Price, subject to Canadian Securities Exchange (“CSE”) approval, will be adjusted so that it will equal the price determined by multiplying the Conversion Price by a fraction, of which the numerator will be the total number of Shares outstanding on such date plus a number equal to the number determined by dividing the aggregate purchase price of the additional Shares offered for subscription or purchase by the closing market price per Share on the day immediately preceding such date, and of which the denominator will be the total number of Shares outstanding on such record date plus the number of the additional Shares.
If during the term of the Warrants, the Company issues warrants with an exercise price below the Exercise Price, the Company will, subject to CSE approval, adjust the Exercise Price downward to the to the greater of (a) the price of such issuance, and (b) the closing market price of the Shares on the CSE on the trading day prior to public dissemination of the news release disclosing the issuance of the Debentures, less the maximum discount permitted by CSE policies. Further, if during the term of the Warrants, the Company issues warrants with an exercise price below the Exercise Price, the Company will, subject to prior approval from the CSE, issue to the Warrant holder special warrants at the reduced exercise price equal to the number of Warrants that would have been issued if the reduced exercise price was used to calculate the number of Warrants issued.
The Debentures will be collaterally secured by: (a) an amended general security agreement constituting a charge and security interest in all of the personal property of the Company; and (b) an unlimited guarantee of certain U.S. based entities of which the Company holds an equity interest consisting of DVG LLC, Elite Ventures Group LLC, Humboldt Holdings, LLC, Ocean Green Management LLC, Wheeler Corridor Business Park LLC, and Wheeler Park Properties, LLC (each, a “Guarantor”) and collaterally secured by security agreements issued by each Guarantor; (c) a pledge of equity interest from the Company relating to the equity interests of each of the Guarantors; and (d) a first priority deed of trust lien on the real property of the Guarantors located in California, Washington and Nevada (collectively, the “Security”). The enforcement of the Security is subject to the terms and conditions of the certificates representing the Debentures (the “Debenture Certificates”) and to an Amended Agency and Interlender Agreement to be entered into among the holders of the Debenture Certificates, the Company, each of the Guarantors, and an agent.
The proceeds of the Offering are expected to be used to continue to grow the Company’s United States operations and for general working capital purposes.
None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP”, in the US on the OTC under the symbol “CRXPF”, and on the Börse Frankfurt (Frankfurt Stock Exchange) under the symbol “2FR”. The Company is focused on owning a portfolio of cannabis branding, CBD and real estate assets through its wholly and partially-owned subsidiaries. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of Hemp CBD farms, and a growing portfolio of share equity in various companies within the cannabis space.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line and 16 cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in CROP Infrastructure, News Home
Mondias announces the results of its annual meeting
Momentum Public Relations
Press Release: June 11, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results of its annual general and special meeting of shareholders (the “Meeting”), which was held yesterday in Montreal, Quebec. All of the nominees listed in the Company’s management information circular dated May 6, 2019, were re-elected as directors.
“This has been a very good first six months for Mondias as a newly listed public company,” said Jean-Philippe Gravel, President and Chief Executive Officer of Mondias. “Our proprietary CELEXT07 bio-defense stimulant plant extract is attracting increasing interest from large players in the agricultural, horticulture and cannabis industries. Our consumer health products sector is also progressing as expected, as we are preparing to launch a new line of sleeping aids products for the second part of 2019. These initiatives, along with others planned for later in the year, will enable Mondias to generate growth and new opportunities in 2019.”
“The Board is pleased with the results obtained to date and is strongly committed in helping Mondias to pursue its strategic growth plan. Our Board has the market expertise and skill set needed to guide the Company in creating value for our shareholders,” added Mr. André Rancourt, Executive Chairman of Mondias.
A total of 43 shareholders were represented in person or by proxy at the Meeting, holding 42,663,175 shares, or 67.57% of Mondias’ issued and outstanding shares.
Detailed results of the vote for the election of directors are set out below:
Nominee |
Votes |
% |
Votes |
% |
André Rancourt |
42,648,175 |
99.96% |
15,000 |
00.04% |
Frank Palantoni |
42,648,175 |
99.96% |
15,000 |
00.04% |
Bertrand Venne |
42,648,175 |
99.96% |
15,000 |
00.04% |
Michel Timperio |
42,648,175 |
99.96% |
15,000 |
00.04% |
Louis Doyle |
42,648,175 |
99.96% |
15,000 |
00.04% |
All other matters presented for shareholder approval at the Meeting were approved, as follows:
- Appointment of UHY McGovern Hurley LLP, Chartered Accountants, as auditors of the Company for the coming year and authorization of the directors to establish their remuneration;
- Amendment and ratification of the Company’s existing stock option plan; and
- Granting of stock options to purchase up to an aggregate of 3,200,000 common shares under the amended rolling option plan.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health-care, bio-agriculture and organic markets. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
Sirona Biochem Reports Approval to Test Higher Concentrations of Skin Lightening Compound TFC-1067
Momentum Public Relations
Press Release: June 11, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona“) is pleased to announce that it will assess its novel skin lightener, TFC-1067, at a concentration 3 times higher than what was used in the previous clinical trial. Higher dosing is expected to have increased efficacy, but also the potential to work more quickly than the clinically effective dose established for TFC-1067. This positive development is of substantial commercial interest to potential cosmetic partners in North America and China who share Sirona’s goal to maximize efficacy without compromising safety.
Previous maximum dosing levels were limited due to technical issues with the standard regulatory in vitrotest used to assess TFC-1067 for skin irritation. A solution to these technical issues has been developed. Sirona’s consultant safety assessor at CEHTRA (https://www.cehtra.com) has now recommended further testing with up to a 3 times higher dose. Several higher doses will be assessed by Idea Lab (https://www.ideatestsgroup.com), experts in safety testing of cosmetics. If the in vitro results of the higher concentrations continue to show no evidence for skin irritation, Sirona will proceed to preparation for clinical testing on humans.
“The clinical effect of TFC-1067 to lessen dark spots or have an overall brightening effect is largely dose dependent”, reports Dr. Howard Verrico, CEO of Sirona Biochem. “We anticipate TFC-1067 will be used at higher doses without adverse effects. While we are pleased with the excellent clinical results achieved so far, being able to test at significantly higher concentrations will likely lead to better clinical effectiveness, potentially faster results and a better range of consumer dosing options.”
“We knew the standard regulatory tests prevented us from utilizing the full potential of TFC-1067 as a skin lightener. We anticipate we will proceed in the future to test our improved formulation combined with higher concentrations of TFC-1067 in further clinical trials. Such testing can be conducted either independently by Sirona or through our anticipated partnerships”, Dr. Verrico added.
The global skin lightening market is expected to reach US$31.2 Billion by 2024.1
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
- Published in Life Sciences, News Home, Sirona Biochem
Mondias announces the results of its annual meeting
Momentum Public Relations
Press Releases: June 11, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results of its annual general and special meeting of shareholders (the “Meeting”), which was held yesterday in Montreal, Quebec. All of the nominees listed in the Company’s management information circular dated May 6, 2019, were re-elected as directors.
“This has been a very good first six months for Mondias as a newly listed public company,” said Jean-Philippe Gravel, President and Chief Executive Officer of Mondias. “Our proprietary CELEXT07 bio-defense stimulant plant extract is attracting increasing interest from large players in the agricultural, horticulture and cannabis industries. Our consumer health products sector is also progressing as expected, as we are preparing to launch a new line of sleeping aids products for the second part of 2019. These initiatives, along with others planned for later in the year, will enable Mondias to generate growth and new opportunities in 2019.”
“The Board is pleased with the results obtained to date and is strongly committed in helping Mondias to pursue its strategic growth plan. Our Board has the market expertise and skill set needed to guide the Company in creating value for our shareholders,” added Mr. André Rancourt, Executive Chairman of Mondias.
A total of 43 shareholders were represented in person or by proxy at the Meeting, holding 42,663,175 shares, or 67.57% of Mondias’ issued and outstanding shares.
Detailed results of the vote for the election of directors are set out below:
Nominee |
Votes |
% |
Votes |
% |
André Rancourt |
42,648,175 |
99.96% |
15,000 |
00.04% |
Frank Palantoni |
42,648,175 |
99.96% |
15,000 |
00.04% |
Bertrand Venne |
42,648,175 |
99.96% |
15,000 |
00.04% |
Michel Timperio |
42,648,175 |
99.96% |
15,000 |
00.04% |
Louis Doyle |
42,648,175 |
99.96% |
15,000 |
00.04% |
All other matters presented for shareholder approval at the Meeting were approved, as follows:
- Appointment of UHY McGovern Hurley LLP, Chartered Accountants, as auditors of the Company for the coming year and authorization of the directors to establish their remuneration;
- Amendment and ratification of the Company’s existing stock option plan; and
- Granting of stock options to purchase up to an aggregate of 3,200,000 common shares under the amended rolling option plan.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health-care, bio-agriculture and organic markets. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include the Company’s inability to obtain sufficient financing to execute its business plan; competition; regulation; anticipated and unanticipated costs and delays; the success of the Company’s research and development strategies; the ability to obtain orphan drug status; the applicability of the discoveries made; the successful and timely completion and uncertainties related to the regulatory approval process; the timing of clinical trials; the timing and outcomes of regulatory or intellectual property decisions; and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company does not undertake any obligation to publicly update them to reflect new information or subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Mondias Natural Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/11/c3543.html
Contact:
Mondias Natural Products Inc., Jean-Philippe Gravel, Chief Executive Officer, 514-804-4569, jpgravel@mondias.ca; L. Derek Lindsay, Vice President, Corporate Development, 514-594-2372, dlindsay@mondias.ca
- Published in Mondias Natural, News Home